

REGULATION OF IMMUNE RESPONSES BY TGF- β *

John J. Letterio and Anita B. Roberts

Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892-5055; e-mail: RobertsA@dce41.nci.nih.gov

KEY WORDS: T cells, B cells, macrophage, dendritic cell, autoimmune disease

ABSTRACT

The transforming growth factor β (TGF- β) family of proteins are a set of pleiotropic secreted signaling molecules with unique and potent immunoregulatory properties. TGF- β 1 is produced by every leukocyte lineage, including lymphocytes, macrophages, and dendritic cells, and its expression serves in both autocrine and paracrine modes to control the differentiation, proliferation, and state of activation of these immune cells. TGF- β can modulate expression of adhesion molecules, provide a chemotactic gradient for leukocytes and other cells participating in an inflammatory response, and inhibit them once they have become activated. Increased production and activation of latent TGF- β have been linked to immune defects associated with malignancy and autoimmune disorders, to susceptibility to opportunistic infection, and to the fibrotic complications associated with chronic inflammatory conditions. In addition to these roles in disease pathogenesis, TGF- β is now established as a principal mediator of oral tolerance and can be recognized as the sine qua non of a unique subset of effector cells that are induced in this process. The accumulated knowledge gained through extensive in vitro functional analyses and from in vivo animal models, including newly established TGF- β gene knockout and transgenic mice, supports the concept that clinical therapies based on modulation of this cytokine represent an important new approach to the treatment of disorders of immune function.

INTRODUCTION

Several established cytokine families are recognized for their roles in regulating the immune response (1). These include the tumor necrosis factor (TNF)-related

*The US government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper.

molecules, the interferons, the chemokines, the interleukins, and the other hematopoietins known to orchestrate the development and function of a variety of immunocompetent cells. Though rarely included under this umbrella of immunoregulatory molecules, the members of the family of transforming growth factors- β (TGF- β) must also be viewed as having a unique and essential role in regulating immune function (2-5). Best known for their roles in development, in epithelial cell growth and differentiation, and in the process of carcinogenesis (6), they are possibly the most pleiotropic, multifunctional secreted peptides known in that they are produced by and act on a wide variety of cell types to regulate endpoints ranging from control of cell growth and differentiation to regulation of cellular function and target gene activity (6).

The three isoforms of TGF- β , i.e., TGF- β 1, 2, and 3, signal through the same serine-threonine kinase type I and type II cell surface receptors and have similar if not identical cellular targets, although each isoform is expressed in a distinct pattern under control of a unique promoter (6, 7). These molecules are now recognized to have profound effects on immune cells, including all classes of lymphocytes, macrophages, and dendritic cells. The action of TGF- β on these cells is dependent not only on the cell type and its state of differentiation, but also on the total milieu of cytokines present (8), suggesting that perturbations of the balance of this cytokine array may also alter effects of TGF- β and contribute to immunopathology. The complex and often context-dependent manner in which TGF- β controls immune responses is gaining greater appreciation, largely through recognition of its roles in experimental models of disease and by evaluation of transgenic and knockout mice with altered expression of these ligands or their receptors (9). In this review we focus on the ability of TGF- β to regulate the function and interaction of cells of the immune system in the development of both humoral and cell-mediated immunity and in immune aspects of disease pathogenesis.

TGF- β REGULATES T CELL DEVELOPMENT AND EFFECTOR FUNCTION

T lymphocytes are clearly influenced by TGF- β at all stages of development, from their differentiation to their activation and proliferation, and can serve as a paradigm for the pleiotropic nature of this cytokine. As in many systems, the effects of TGF- β on T cells are, in part, a function of their state of differentiation, and such effects often are altered by the nature of the activating signals (10, 11). The earliest studies of the effects of TGF- β on human lymphocyte function revealed that activated T cells themselves synthesize and secrete TGF- β and that exogenous TGF- β typically inhibits IL-2-dependent proliferation (12). Several studies have highlighted these inhibitory effects of

TGF- β , particularly its ability to interfere with events that occur subsequent to IL-2 production and receptor binding (13) such as the production of various cytokines (14–16) and cytolytic functions (17, 18).

In contrast to the many inhibitory effects of TGF- β on T lymphocytes delineated by these early studies, a growing body of literature demonstrates that TGF- β can also enhance the growth of T cells, predominantly of the naive phenotype (19), induce T cell expression of specific cytokines and enhance their capacity to respond to subsequent stimulation, and even promote effector expansion through inhibition of T cell apoptosis (20–22). Though these differential activities appear to be contradictory, they exemplify the common association between cellular differentiation or activation status and effect of TGF- β that exists in most responsive cell types. We expand this discussion below in an overview of the roles of TGF- β in thymocyte development and T_{H1} - T_{H2} differentiation.

Autocrine and Paracrine Effects of TGF- β During Normal Thymopoiesis

Early thymocytes progress through a series of differentiation steps largely defined by their expression of specific receptor molecules (23, 24). These cells undergo extensive proliferation promoted by a number of cytokines, including IL-2, IL-4, and IL-7, and their development from the T cell receptor negative (TCR $^{-}$), CD4 $^{-}$ CD8 $^{-}$ (triple negative, TN) thymic precursor into either the CD4 $^{+}$ or the CD8 $^{+}$ single positive (SP) populations is controlled by a variety of cellular interactions. Through in vitro studies of thymopoiesis, roles for both autocrine and paracrine TGF- β have now been defined.

TGF- β was first reported to induce CD8 expression in studies designed to determine the influence of various cytokines on the differentiation of murine thymic TN cells to either the CD4 $^{+}$ or the CD8 $^{+}$ SP populations. IL-7 can maintain the viability of IL-2 receptor negative (CD25 $^{-}$) early TN thymocytes, including their capacity to differentiate fully in vitro in a lymphoid-depleted fetal thymus organ culture system (25). TGF- β synergizes with TNF- α to promote or favor the development of thymic precursor cells expressing CD8 (26). Furthermore, these thymic precursors treated with TGF- β and TNF- α retained the capacity to differentiate fully when transferred to fetal thymus organ culture, suggesting that this TGF- β -induced expression of CD8 on CD25 $^{+}$ TN thymocytes represents a normal differentiation step (25).

The ability of TGF- β to regulate the expression of CD8 is not restricted to thymic precursors. Inge and colleagues found that TGF- β alone could enhance de novo CD8 expression not only on CD4 $^{-}$ CD8 $^{-}$ thymocytes, but also on the IL-2-dependent CTLL-2 cytotoxic T cell line (27). The induction of CD8 in CTLL-2 cells was dependent on the continuous presence of TGF- β , was not a consequence of growth arrest, and was in contrast to the ability of TGF- β to

inhibit IL-2-dependent increases in IL-2R α , IL-2R β , and Granzyme B mRNA levels in these cells.

TGF- β IN THE CONTEXT OF CELLULAR INTERACTIONS IN THE THYMUS More recent studies examine the role of specific cellular interactions in these events and point toward both autocrine and paracrine TGF- β activity in normal thymopoiesis. One such study focused on the inhibitory effects of TGF- β on the *in vitro* proliferation of freshly isolated human triple negative thymocytes in response to IL-2, IL-4, and IL-7 (28). The dramatic inhibitory effect of TGF- β on these proliferative responses was mimicked by the coculture of these thymocytes with autologous irradiated CD8⁺ T cells, but not their cell free supernatants. Cell fixation studies determined that the thymocytes themselves produce a latent TGF- β 1 that could only be activated through the interaction of TN cells with the CD8⁺ cells, thus identifying TGF- β 1 as an autocrine inhibitory factor for early human thymocytes.

Studies of murine thymocyte development in fetal organ culture further substantiate the role of TGF- β in early thymopoiesis (29) and also implicate potential paracrine mechanisms involved in this process. The progression of CD4⁻CD8⁻ thymocytes to CD4⁻CD8^{lo}, and to the subsequent CD4⁺CD8⁺ stages show that differentiation into the double positive state requires progression through at least one cell division, an event that is effectively inhibited by thymic epithelial cells expressing TGF- β (30). The effect is specific for this stage of development in that the generation of CD4⁻CD8^{lo} cells is unaffected.

Thus, it is likely that both paracrine and autocrine mechanisms participate in a complex regulatory loop to control thymopoiesis. This may include the regulation of stromal cell production of stimulatory cytokines, such as IL-7, by TGF- β produced by thymocytes (31, 32). As noted above, TGF- β produced either by thymic precursors or thymic epithelial cells can affect the development of thymocytes, particularly their response to stimulatory cytokines such as IL-7.

A Role for TGF- β in the Development of Specific T_H Responses

Our understanding of the process of differentiation from a naive, peripheral CD4⁺ T cell into distinct T_H subsets with unique cytokine profiles and functions continues to increase. There are multiple pathways for the initiation of this differentiation into any of these functionally polarized T_H subsets, and certain cytokines are clearly established as inducers of either the T_{H1} (IFN- γ and IL-12), or the T_{H2} (IL-4) response (reviewed in 33) (see Figure 1). More recent studies have focused on determining not only the cellular origin of these cytokines, but also the mechanisms controlling their production (34, 35). Even though expression of these cytokines remains the hallmark of their respective T_{H1} or




Figure 1 The characteristic production of active TGF- β by a specific subset of T_H cells is now recognized as an important factor in the establishment of oral tolerance. While this subset produces cytokines characteristic of the T_{H2} class of effector cells, the secretion of TGF- β is critical to their ability to suppress an inflammatory response. Although the exact requirements for the establishment of these TGF- β -secreting cells remained to be defined, the progress is clearly antagonized by factors that promote differentiation toward a T_{H1} response.

T_{H2} subset, the recent identification of differential expression of the $\beta 2$ chain of the IL-12 receptor on these two cell populations shows this subunit to be a distinct marker of T_{H1} cells, in both mice (36) and humans (37).

While different experimental systems have produced conflicting data regarding the influence of TGF- β on T_H differentiation, clearly TGF- β can inhibit the production of and response to cytokines associated with each subset, and the production of TGF- β by antigen-specific T cells may mark a unique subset already referred to as T_{H3} (38–40). Initial studies of the exposure of naive CD4⁺ cells to TGF- β during their priming phase suggested that this factor would push differentiation toward a T_{H1} phenotype, with the primary result being an increase in INF- γ -producing cells and a decrease in IL-4-producing cells (41). This effect has also been observed in a murine IL-2-secreting CD4⁺

T cell clone (42), and in cultures of directly alloresponsive human CD4⁺ T cells when TGF- β is included in a mixed lymphocyte culture (MLC) performed with purified responder T cells (43). However, the significance of these observations has been questioned, particularly since systemic administration of TGF- β in mice infected with *L. amazonis* or *L. brasiliensis* leads to increased production of the T_{H2} cytokine, IL-4, and decreased production of the T_{H1}-associated IFN- γ , and ultimately results in a greater severity of disease (44).

Further studies appear to have more clearly aligned TGF- β exposure with T_{H2} differentiation by virtue of its reciprocal relationship with both IFN- γ and IL-12 (45). For example, exposure of naive murine CD4⁺ T cells to IL-12 during activation with anti-CD3 monoclonal antibody (mAb), in the absence of accessory cells, not only leads to autocrine production of IFN- γ , but synergizes with IFN- γ to induce T_{H1} differentiation (46). However, simultaneous exposure to TGF- β strongly inhibits this induction of IFN- γ in response to IL-12 and suppresses IL-12-induced T_{H1} development, an effect that is enhanced by the addition of anti-IFN- γ neutralizing antibodies (46). This functional interaction between TGF- β and IL-12 has also been observed in human primary allogeneic proliferative and cytotoxic T cell responses (47), in which the effects of TGF- β are mediated through mechanisms associated with the abrogation of IL-12 production. This response cannot be reversed even with the addition of exogenous IL-12 or IFN- γ .

This antagonistic relationship between IL-12, IFN- γ , and TGF- β may also be a factor in the induction of peripheral tolerance following the oral administration of antigen (48). In several animal models of autoimmunity, and in their respective disease counterparts in humans, the ability to ameliorate disease severity through this mechanism is linked to the establishment of a T_{H2}-like subset that is further distinguished by its ability to secrete bioactive TGF- β (38). This process has been modeled in ovalbumin (OVA)-T cell receptor (TCR) transgenic mice, in which the oral administration of high doses of OVA leads to local T cell expression of IFN- γ in Peyer's patches, followed by systemic unresponsiveness due primarily to clonal anergy rather than the suppressor cytokine production typically seen with low dose oral antigen (49). This predominance of T_{H1} cytokines, including IL-12, effectively inhibits the establishment of TGF- β -secreting suppressor T cells. More importantly, the concomitant systemic administration of anti-IL-12 blocking antibodies not only significantly enhances TGF- β production in this model, but this induction is completely independent from any effect on IL-4 production, further distinguishing these suppressor cells as a potentially distinct T_H subset (see Figure 1). This conclusion is also supported by models of inflammatory bowel disease in which TGF- β -producing CD45RB^{lo} T cells protect against colitis induced in SCID mice following their reconstitution with CD45RB^{hi} T cells, even when the CD45RB^{lo} cells are from an IL-4^{-/-} donor (50).

TGF- β INFLUENCES DENDRITIC CELL DEVELOPMENT AND FUNCTION

Dendritic cells (DC) are a distinct population of leukocytes that function as the primary antigen-presenting cells in the activation of T lymphocyte responses (51). Several highly specialized populations of dendritic cells, including the Langerhans cells (LC) of the epidermis and the follicular dendritic cell (FDC) of lymph nodes, have been identified, and TGF- β may both regulate their development and mediate their effects.

A Role for TGF- β 1 in the Generation of Dendritic Cells

The recent discovery of a requirement for TGF- β 1 during the *in vitro* differentiation of functional dendritic cells identified a new role for TGF- β in regulating these specialized antigen presenting cells (52). Though *in vitro* differentiation of DC from cultures of CD34⁺ precursor cells is dependent on the presence of specific cytokines, such as TNF- α , SCF, and GM-CSF, it is greatly enhanced by the addition of exogenous TGF- β 1, which can effectively substitute for the serum or plasma requirement in this system. Further studies determined that TGF- β protects DC viability, as demonstrated by a reduction of more than 60% in the number of apoptotic cells at 72 h in culture (53).

The importance of TGF- β 1 in DC development is also emphasized by recent studies in the TGF- β 1 knockout mouse, where the complete absence of the epidermal LC is a striking feature of the phenotype (54), which also includes the generalized activation of most immune cell populations and widespread tissue inflammation (55, 56). The loss of epidermal LC is a consistent defect in TGF- β 1 null mice whether they are bred onto a variety of immunodeficient backgrounds (SCID, athymic nude, RAG2-null) or maintained on the immunosuppressive agent rapamycin, so it appears unlikely that inflammatory cytokines are effecting migration of LC from the TGF- β 1-null epidermis (54). This absence of epidermal LC may reflect an absence of precursor populations or perhaps some defect in their homing to the epidermis. However, transplantation of TGF- β 1-null marrow into wild-type, lethally irradiated recipients leads to repopulation of recipient skin with donor-derived LC, implying that normal LC progenitors exist in the TGF- β 1 null mouse bone marrow, and that paracrine sources of TGF- β 1 are sufficient to support normal LC development and perhaps even their migration into the epidermis (57).

TGF- β and Follicular Dendritic Cells

TGF- β may also have an important role in another highly specialized class of antigen-presenting cell, the follicular dendritic cell (FDC). Localization of TGF- β within the FDC of lymphoid follicles (58), combined with its ability to inhibit antigen-induced rescue of germinal center (GC) B cells, suggests

there is specific function for TGF- β in FDC. While these FDC, which have the capacity to take up antigen and display it on their surface for more than a year, express receptors for several cytokines, TGF- β is the only one they are known to produce (58). The surface of the FDC is the site of primary selection events in B cells that have undergone activation, clonal expansion, and somatic hypermutation of Ig ν^- region genes (centrocytes). Antigen trapped on the surface of FDC provides an effective survival signal for centrocytes with high-affinity surface membrane immunoglobulin (smIg), and TGF- β is the only factor known to interrupt this signal (59). This effect is specific, in that the survival signals initiated through CD40 are not inhibited by TGF- β ; this may represent a regulatory mechanism to prevent the selection of centrocytes with low-affinity receptors bearing autoreactive mutations (60). Finally, the fact that TGF- β 1 null mice also lack gp40⁺ lymph node DC, despite normal numbers of CD11c⁺ DC, suggests that the loss of TGF- β 1 may affect other specialized DC populations participating in extrafollicular immune responses (54).

TGF- β PRODUCTION AND RESPONSIVENESS IN B CELLS

A Link Between Activation and TGF- β Expression in B Cells

As in most immune cell populations, the synthesis, secretion, and response to TGF- β in B cells are often a consequence of their state of differentiation and the activation signals involved. For example, the activation of human tonsillar B cells with the polyclonal mitogen *Staphylococcus aureus* Cowan (SAC) only slightly upregulates TGF- β 1 mRNA expression, but results in a sevenfold induction of TGF- β 1 protein secretion, over 90% of which remains in the latent or inactive form (61). These effects contrast with those of another polyclonal B cell activator, lipopolysaccharide (LPS), which stimulates mouse splenic B cells to produce bioactive TGF- β (62). This autocrine TGF- β is required for the secretion of IgG by B cells in response to LPS in vitro. Activation through antigen receptor by binding a monoclonal anti-IgM antibody to cell surface IgM induces expression of TGF- β 1 mRNA in normal human peripheral blood B cells and stimulates murine B-lymphoma cell lines to secrete large amounts of active TGF- β 1 (63, 64). Given that TGF- β typically inhibits B cell proliferation and may induce apoptosis in both B cells (59, 65) and in the fully differentiated plasma cells (S Amoroso, N Huong, A Roberts, M Potter, J Letterio, manuscript in preparation), this induction of TGF- β likely serves as an important regulatory feedback loop to limit expansion of an activated population. This autocrine inhibitory loop remains intact in some B lymphoid malignancies and has been

implicated in their reduced proliferative responses and slow rate of progression (66, 67). However, it is interesting that several murine and human B lymphoid malignancies have been identified that have become insensitive to the growth inhibitory effects of TGF- β and that express substantial amounts of an active form of the molecule (68–70). This association is common in epithelial malignancies and may be important in tumor progression and in suppression of immune surveillance (71).

B Cell Differentiation and Immunoglobulin Production Are Regulated by TGF- β

TGF- β controls several aspects of the normal maturation and differentiated functions of B cells, in addition to its effects on B cell proliferation. This includes the regulation of expression of cell surface molecules, including the inhibition of IgM, IgD, IgA, κ and λ chains, CD23 (Fc ϵ RII) and the transferrin receptor, and the induction of MHC class II expression on both pre-B and mature B cells (reviewed in 72). The ability of TGF- β to direct switch recombination in immunoglobulin isotypes IgA and IgG2b in mouse and IgA in human appears to be due to the induction of transcription from the unrearranged I α -C α and I γ 2b-C γ 2b gene segments, but the specific events that lead to this switching and whether TGF- β is even essential are not yet known (72). Indeed, although the loss of endogenous TGF- β 1 gene expression in the TGF- β 1-null mouse results in the production of autoantibodies (predominantly IgG), it does not lead to a diffuse polyclonal hypergammaglobulinemia nor to a predominance of an Ig clonotype (73).

While TGF- β is noted for this ability to inhibit immunoglobulin synthesis and the secretion Igs of all classes, here too there can be a dichotomy in the response to TGF- β . Most studies demonstrating this inhibitory effect have investigated the effects of addition of exogenous TGF- β to cultures of activated B cells. In a revealing study by Snapper et al (62), the addition of an anti-TGF- β blocking antibody to LPS-activated cultures led to a significant decrease in the secretion of IgG1, IgG2a, IgG3, and IgE, without an effect on IgM, suggesting that low levels of autocrine TGF- β may actually serve to enhance production and secretion of immunoglobulins under certain conditions.

CONTROL OF MONOCYTE/MACROPHAGE FUNCTION BY TGF- β

Cells of the mononuclear phagocyte system function both as accessory antigen-presenting cells in the induction of immune responses and as effector cells in mediation of certain responses. Monocytes/macrophages secrete TGF- β , which can also regulate a broad spectrum of their activities from chemotaxis, to host

defense, to activation and deactivation as mediated by expression of cytokines and their receptors and small effector molecules such as reactive oxygen species and nitric oxide (for a review, see 74). As such, these cells mediate many of the effects of TGF- β on inflammation (reviewed in 4, 75) and, indirectly, on pathological fibrosis associated with chronic inflammation (reviewed in 76).

Expression and Activation of TGF- β by Monocytes/Macrophages

As is the case for all cell lineages derived from the bone marrow, both circulating monocytes and tissue macrophages secrete TGF- β , predominantly as the type 1 isoform (77, 78). In macrophages, as in lymphocytes, the primary level of control is not in the regulation of expression of TGF- β mRNAs, but in the regulation of both the secretion and activation of latent forms of TGF- β . Thus, treatment of peripheral blood monocytes with bacterial lipopolysaccharide (LPS) or of alveolar macrophages with concanavalin A results in significant increases in secreted active TGF- β 1 without changes in the level of TGF- β 1 mRNA (77, 78).

Activation of the latent forms of TGF- β , which are blocked from receptor binding, is an important posttranscriptional control point in both physiological and pathological actions of TGF- β (79, 80). Specific mechanisms of activation of TGF- β by LPS-treated thioglycollate-elicited peritoneal macrophages include complex cooperativity between the serine proteases plasmin and urokinase (uPA), the uPA receptor, tissue type II transglutaminase, and the mannose-6-phosphate receptor (81). Expression of active TGF- β 1 by macrophages and other leukocytes plays a central role not only in inflammation, but also in accompanying fibrosis by paracrine stimulation of resident mesenchymal cells to produce excessive extracellular matrix. Thus, in bleomycin-induced pulmonary fibrosis in mice, nearly all of the active TGF- β implicated in pathologic matrix deposition is secreted by alveolar macrophages and is temporally concordant with the deposition of collagen in the lung (82). In these cells, activation of latent TGF- β is dependent both on plasmin and on binding of the latent complex to the cell membrane via thrombospondin-1 (TSP-1) and its receptor, CD36, expressed on the surface of monocytes and macrophages (82–84) (Figure 2). These findings suggest that the mannose-6-phosphate receptor and transglutaminase might also serve to anchor latent TGF- β to the cell surface to optimize proteolysis and activation by plasmin. Studies with human THP-1 macrophage-like cells show that TGF- β itself may contribute to its activation by macrophages. Adherent THP-1 cells respond to TGF- β by upregulation of uPA and its receptors, essential components in the regulation of macrophage plasminogen activation, resulting in a threefold increase in membrane-bound plasmin activity (85). Parasitic infection of macrophages




Figure 2 Activation of latent TGF- β by macrophages is key to both its physiological and pathological actions on immune cells. Following processing of pre-pro TGF- β to its latent complex, the secreted latent TGF- β is anchored to the macrophage membrane via TSP-1 bound to its receptor, CD36, and activated by cell membrane bound plasmin (84). Macrophages can also activate IgG-TGF- β complexes secreted by plasma cells by binding these complexes to cell membrane Fc receptors (119, 121). Alternatively, certain IgG-TGF- β complexes may be intrinsically active (120). Active TGF- β then signals through its cell surface receptor in an autocrine or paracrine mode.

also results in activation of secreted TGF- β , as discussed in greater detail below, although the particular mechanisms involved have not yet been identified.

Activation of Macrophage Function by TGF- β

Similar to the pleiotropic effects of TGF- β on lymphocyte subsets, effects of TGF- β on proliferation of macrophages can be either stimulatory or inhibitory, depending on the other cytokines present and the state of differentiation or tissue origin of the cells (86–88). Femtomolar concentrations of TGF- β induce a chemotactic response in human peripheral blood monocytes, a response that likely plays a critical role in the recruitment of mononuclear cells into sites of injury or inflammation (89–91). Picomolar concentrations of TGF- β activate resting human blood monocytes to express increased levels of mRNAs encoding

a variety of cytokines including IL-1 α and β , TNF- α , PDGF-BB, and bFGF, which indirectly affect various immune processes as well as non-immune targets as in angiogenesis (89–91). Other proinflammatory effects of TGF- β on leukocytes include its ability to increase expression of several integrin receptors on monocytes including LFA-1, which binds ICAM-1 expressed on the surface of endothelial cells; VLA-3 ($\alpha_3\beta_1$), which binds collagen, fibronectin, and laminin; and VLA-5 ($\alpha_5\beta_1$), which binds fibronectin, thereby increasing both cell-cell and cell-matrix interactions (92, 93). This enhanced expression of adhesion receptors as well as of type IV collagenase by activated monocytes likely enhances their penetration of the basement membrane of vascular endothelium and their subsequent transmigration into tissues (93). As in other responses, IFN γ can antagonize certain of these effects of TGF- β on cellular adhesion, suggesting that the cytokine balance may regulate leukocyte motility within sites of inflammation (94).

The phagocytic activity of monocytes/macrophages is also activated by TGF- β . One such mechanism involves its ability to stimulate circulating monocytes to upregulate expression of cell surface Fc γ RIII, which recognizes bound IgG and is thought to play a key role in immunophagocytosis (95). A second mechanism involves a TGF- β -dependent increase in macrophage recognition of phosphatidyl serine, which, though normally localized to the inner membrane, is expressed on the outer membrane leaflet of apoptotic cells (96). Thus TGF- β contributes both to the formation of inflammatory foci by direct effects on chemotaxis and adhesion and to the resolution of acute inflammatory reactions and restoration of homeostasis by increasing the phagocytic activity of macrophages toward inflammatory cells and damaged parenchymal cells.

Deactivation of Monocytes/Macrophages by TGF- β

In contrast to the activating effects of TGF- β on peripheral blood monocytes, its actions on tissue macrophages are generally suppressive and contribute to the resolution of an inflammatory response. This has been attributed, in part, to a dramatic difference in the expression pattern of receptors for TGF- β on these two populations of the mononuclear phagocyte system. Resting monocytes express high levels of TGF- β type I and II receptors, whereas receptor levels decline as cells mature and then become activated by agents such as LPS or IFN γ (4). Examples of suppressive effects of TGF- β on activated macrophages are its ability to modulate the profile of activating cytokines as by limiting production of IFN γ (15) or increasing expression of the IL-1 receptor antagonist (97) similar to effects of IL-4, IL-10, and macrophage deactivating factor (MDF) (74). This also parallels the role of TGF- β in resolution of inflammation in models of inflammatory bowel disease, where there is suggested to be a deficiency in elaboration of suppressive cytokines such as IL-1 receptor antagonist, IL-4,

IL-10, and TGF- β to counterbalance the pro-inflammatory cytokines such as IFN γ and TNF α , which are produced in response to the constant luminal exposure to antigens (45, 98).

SUPPRESSION OF NITRIC OXIDE AND REACTIVE OXYGEN INTERMEDIATES Possibly the most important deactivating effect of TGF- β on macrophages is its ability to limit the production of cytotoxic reactive oxygen and nitrogen intermediates by cells activated by either IFN γ or LPS (for reviews, see 74, 99). The enzyme responsible for production of nitric oxide by activated macrophages is an inducible form of nitric oxide synthase (iNOS). Regulation of this enzyme by cytokines including TGF- β is now known to underlie control of the antimicrobial and tumoricidal pathways of macrophages and of immune responses in general (74). TGF- β regulates iNOS at both transcriptional and posttranscriptional levels, resulting in downregulation of iNOS mRNA levels and suppression of both the expression and activity of iNOS protein. The latter effects are still observed even when TGF- β is added to cultures after expression of iNOS is maximal (99). TGF- β also suppresses expression of reactive oxygen intermediates and respiratory burst capacity by both resting blood monocytes (100) and activated macrophages (101), but the mechanisms involved are still unknown.

SUPPRESSION OF MACROPHAGE FUNCTION IN PARASITIC INFECTION TGF- β is now recognized as an important immunoregulator and parasite escape mechanism in all forms of human and murine leishmaniasis, a parasitic disease with both tegumentary and visceral effects, depending on the strain. Protozoan parasites such as *Trypanosoma cruzi*, which infect all nucleated cells (102), and *Leishmania*, for which macrophages serve as the exclusive cellular host (44, 103), have evolved mechanisms to induce the infected host cell to secrete active TGF- β , which then suppresses the killing activity of macrophages and enhances intracellular proliferation of the pathogen. Fascinating studies with *T. cruzi* suggest that autocrine signaling of TGF- β is required for parasite entry into cells: Epithelial cells lacking TGF- β receptors are resistant to trypanozome infection and infectivity is restored following transfection of functional TGF- β receptors (104). In vitro experiments demonstrate that the amount of active TGF- β produced by macrophages upon infection with various strains of *Leishmania* promastigotes correlates roughly with both the strain virulence and the proliferation of parasites within the macrophage (105). Moreover, studies in mice demonstrate a role for endogenous TGF- β in susceptibility to infection in that systemic administration of TGF- β increases the infectivity of relatively avirulent strains of *Leishmania* and reverts the genetic resistance of certain strains of mice to infection, whereas systemic administration of antibodies to

TGF- β arrests development of lesions in susceptible mice (44). Similar results are found with *T. cruzi* infection in mice (106).

Both resistance to and recovery from leishmaniasis are related to cell-mediated immune responses. Two mechanisms are proposed to explain the disease-enhancing effects of TGF- β in leishmaniasis, and each depends on the balance of the cytokine milieu. One involves the ability of TGF- β to decrease cell-mediated immunity by suppressing effects of IFN γ or IL-4 on expression of MHC class II antigen on antigen presenting cells (107, 108). The second mechanism is related to the ability of TGF- β to modulate the activity and differentiation of CD4⁺ and CD8⁺ T cell subsets. Thus in patients with the destructive mucosal form of leishmaniasis, TGF- β inhibits cytotoxic CD8⁺ T cells, which are thought to play a role in elimination of infected cells (109). And in mice, a T_{H2}-like response with accompanying increased production of IL-4 and IL-10 is found in regional lymph nodes of susceptible strains, whereas in resistant mice, a T_{H1}-type response predominates with production of IL-2 and IFN γ , which promotes leishmanicidal activity by enhanced production of cytotoxic oxygen and nitrogen radicals (103). As discussed above, TGF- β appears to play a direct role in modulation of these T_H cell subsets (see Figure 1).

Infection of macrophages with the intracellular bacteria *Mycobacterium avium* also increases macrophage production of active TGF- β and suppresses their antibacterial activity, suggesting that a variety of infectious agents may have developed similar mechanisms for their survival and proliferation in a mammalian host (110).

ROLE OF TGF- β IN AUTOIMMUNE DISEASES

In autoimmune disease, the normal ability to distinguish between self and non-self is disturbed. Many lines of evidence implicate TGF- β in the pathogenesis of autoimmune diseases. Studies of experimental allergic encephalomyelitis (EAE) and collagen-induced arthritis (CIA) in mice and rats demonstrated that systemic administration of TGF- β suppressed the symptoms of the disease, whereas antibodies to TGF- β enhanced the disease process, demonstrating that endogenous TGF- β has a suppressive effect on disease progression (111–114). TGF- β also mediates certain aspects of peripheral immune tolerance induced by oral administration of antigens. Both CD4⁺ and CD8⁺ suppressive T cell subsets that secrete active TGF- β 1 have been identified following induction of oral tolerance (115), and the protective function of these cells both in vitro and in vivo can be blocked by antibodies to TGF- β (38, 114). Consistent with these observations, mice in which the TGF- β 1 gene has been deleted by homologous recombination develop a phenotype characterized by numerous hallmarks of autoimmune disease (for a review, see 116). All of these data support a model

in which TGF- β actively participates in the development of self-recognition and plays an essential role in the maintenance of self-tolerance, as discussed in greater detail below.

Mechanisms of Action of TGF- β in Autoimmune Disease

STUDIES IN THE MRL/LPR MOUSE Several new insights into pathologic TGF- β activation and trafficking and its regulation of immune cell activity have come from the study of the MRL/lpr mouse, a murine model of systemic autoimmunity. These mice, which uniformly develop systemic autoimmune disease resembling human systemic lupus erythematosus (SLE), have a mutation in the gene encoding Fas that results in defective apoptosis, one of the key mechanisms responsible for deletion of self-reactive lymphocytes (117).

Study of the MRL/lpr mice has demonstrated that these mice have elevated levels of circulating plasma TGF- β 1 bound to IgG autoantibodies (118–120). Unrelated studies show that mice repeatedly immunized with an antigen carry TGF- β 1 on a small fraction of the specific IgG induced, and that this complex suppresses CD8⁺ CTL responses in mixed lymphocyte cultures, but only in the presence of macrophages (121). The demonstration that this suppression could be blocked by an antibody to Fc receptors suggests a novel regulatory circuit in which antigen-specific IgGs are processed by macrophages to suppress CTL responses to unrelated antigens (see Figure 2). Given the highly pleiotropic nature of TGF- β , it has been proposed that its binding to IgG could restrict or direct its activity to antigenic sites where it plays important roles in the homeostasis of immunity and suppression of autoimmune disease (121).

Elevated circulating levels of IgG-bound TGF- β 1 are found not only in the MRL/lpr mice, but also in pristane-induced systemic autoimmunity in Balb/c mice and, importantly, in the plasma of some patients with SLE (118–120). Two consequences directly attributable to these increased levels of IgG-bound TGF- β 1 in plasma are increased susceptibility to infection by gram-negative and gram-positive bacteria and defects in polymorphonuclear leukocyte (PMN) function as assayed by their inability to extravasate into the thioglycollate-inflamed peritoneum and failure to amplify phagocytic function in response to stimulation by phorbol ester or the chemotactic peptide FMLP (118, 120, 122). Importantly, the IgG bound form of TGF- β 1 is consistently 10–500-fold more active than uncomplexed recombinant TGF- β 1 in mediation of effects on immune cells both in vitro and in vivo, suggesting that targeting of this TGF- β complex to the cell surface, possibly via Fc receptors, may increase its propensity to interact with signaling receptors on immune cells and possibly even modulate its receptor binding in such a way as to augment its effects (120, 121).

Whereas total plasma levels of TGF- β 1 in MRL/lpr mice are only about double that of congenic control mice, plasma levels of IgG-bound TGF- β 1 are

nearly 150-fold higher than the controls, with about 75% of the total plasma TGF- β 1 in MRL/lpr mice bound to IgG (120). Both immunohistochemical data and in vitro assay of culture supernatants of cells purified from MRL/lpr mice identify B cells and plasma cells as the source of the circulating IgG-bound TGF- β 1 (120). Notably, greater than 80% of the secreted TGF- β 1 complexed to IgG is in the active form, suggesting that the pathogenicity of this complex may derive not only from the specific targeting imparted by the bound IgG, but also from loss of regulation of the activation of latent TGF- β .

Many aspects of this important mechanism are still unknown (see Figure 2). For example, whether TGF- β can associate with any other immunoglobulin isotypes is not known, and whether mature or latent TGF- β 1 associates with specific IgGs intracellularly prior to secretion (119, 120) or associates with IgG extracellularly (121, 123) is still controversial. Moreover, since TGF- β appears to associate only with IgG autoantibodies and antibodies raised in response to specific immunization (120, 121), it is important to identify the precise determinants of IgGs that mediate the interaction with TGF- β and whether the binding is isoform specific. Thus, the demonstration that glomerulopathic but not tubulopathic monoclonal κ light chains are associated with TGF- β -like effects on mesangial cells, implicating TGF- β in the pathogenesis of light chain deposition disease (124), does not exclude the interpretation that glomerulopathic light chains might actually bind TGF- β and that the variable region of the light chain might be the site of TGF- β binding to IgG. However, studies demonstrating the ability of TGF- β to mimic an IgG-binding factor, thought to be important in negative-feedback inhibition of IgG and IgM antibody production by B cells (123), show that TGF- β can bind insolubilized IgG but not F(ab')₂ (123). Based on these observations, the possibility that TGF- β might bind to both the variable region and the Fc domain of IgG cannot be excluded. Interesting in this regard, activation of latent TGF- β by binding to TSP-1 involves the bimodal interaction of a WSXW motif with mature TGF- β followed by interaction of another sequence, RFK, with the amino terminus of the latency-associated protein (LAP) (125). Binding of this TSP-1/TGF- β 1 complex to macrophages via the CD36 receptor represents another mechanism for targeting TGF- β complexes, though with an additional level of control by plasmin (84).

In summary, active TGF- β 1/IgG complexes secreted by B cells and plasma cells and interacting, in certain cases, with cellular Fc γ receptors may be found to modulate B cell responses, to mediate immunosuppressive effects on both T cells and neutrophils in a broad spectrum of diseases, and possibly to participate in physiological trafficking of TGF- β 1 as proposed for the transfer of maternal TGF- β 1 to fetuses and neonates (126).

AUTOIMMUNE DISEASE IN THE TGF- β 1 NULL MOUSE Mice null for the TGF- β 1 gene clearly illustrate that this isoform is a critical regulator of immune cell

differentiation and function, and further, that loss of this gene is sufficient for development of an autoimmune-like phenotype including enhanced expression of MHC class I and II antigens, circulating SLE-like IgG antibodies to nuclear antigens, pathogenic glomerular IgG deposits, and a progressive infiltration of lymphocytes into multiple organs similar to that seen in human autoimmune syndromes such as Sjögren's disease (73, 127, 128; for a review, see 116). The inflammatory infiltrates compromise organ function and contribute to the death of these mice at about 3 weeks. Although tissue infiltration can be blocked by systemic administration of fibronectin peptides, which block adhesion of TGF- β 1-null leukocytes to endothelium, this treatment does not block the primary autoimmune response (129). In contrast, aberrant expression of the MHC class I and II antigens clearly represents an important mechanism in development of this autoimmune phenotype because backcrosses of the TGF- β 1 null mice onto either an MHC class I- or class II-deficient background develop neither circulating autoantibodies nor immune complex deposits (130). TGF- β 1 is known to suppress expression of MHC class II antigen (107, 131), consistent with its overexpression in TGF- β 1 deficiency. Since MHC class II molecules play a role in the selection and activation of CD4⁺ T cells, which regulate both humoral and cell-mediated immune responses to antigens, the suppression of the autoimmune phenotype in TGF- β 1(-/-)/MHC-II(-/-) mice also derives, in part, from the absence of this T cell subset in the MHC-II-null background (130).

Role of TGF- β in Immunologic Tolerance

The term tolerance describes the process whereby the immune system distinguishes self from nonself to prevent pathologic reactivity against self-antigens. Development of autoimmunity is normally prevented by selection processes operative during lymphocyte maturation that result in apoptosis of self-reactive clones and by mechanisms that maintain or establish tolerance in peripheral tissues. Data suggest that TGF- β can contribute to both of these processes. In the thymus, negative selection ordinarily takes place at the CD4⁺CD8⁺ "double positive" stage of T cell development and involves recognition of MHC class II molecules (30). Since TGF- β regulates the maturation of these doubly positive cells from their CD4⁻CD8^{lo} precursors, it is possible that, in the absence of TGF- β 1, doubly positive thymocytes are generated too rapidly for their appropriate elimination (30). Dysregulated production of CD4⁺CD8⁺ T cells in these mice may be exacerbated by defects in apoptosis of T cell subsets, as suggested by preliminary data (JJ Letterio, unpublished).

Mechanisms involved in the maintenance of peripheral tolerance include clonal anergy and a delicate balance of reactive and suppressor T cells and their respective cytokines (see Figure 1). Thus in the EAE model, oral tolerization with myelin basic protein induces peripheral tolerance by generating both a

population of CD8⁺ T cells that secretes active TGF- β 1 and a regulatory population of CD4⁺ T_{H2}-like cells producing IL-4, IL-10, and secreting TGF- β 1 in an antigen-specific manner (38, 114, 115). Since only a subset of the T_{H2} clones isolated produced TGF- β 1, and since the cytokine profile of these cells is stable on prolonged culture, these cells may constitute a novel T cell subset (T_{H3}) with mucosal T helper function and suppressive activity for T_{H3} cells (38). The suppression of disease is proposed to be mediated by inhibition of the autoimmune responses by TGF- β 1 secreted by these mucosally derived cells at the target organ. Importantly, a similar distinct subset of T_{H3} cells has been identified in multiple sclerosis patients treated for 2 years with oral antigen (39). Some evidence suggests that the cytokine profile can drive the preponderance of specific T_H cell subsets. As shown in Figure 1, antibodies to IL-12 or IFN γ enhance expression of TGF- β , presumably by a T_{H2}-like or possibly T_{H3} T cell subset (45, 48). Disruption of this tightly controlled cytokine network, as by the loss of TGF- β 1, can potentially upset the normal regulation of self-reactivity and contribute to the development of systemic autoimmunity by disturbing the delicate balance between T_{H1} and T_{H2} cells (116). Although the direct involvement of such a mechanism remains to be demonstrated for autoimmune disease in humans, in murine models of inflammatory bowel disease there is now substantial data to support antagonistic effects of pro-inflammatory (T_{H1}) and anti-inflammatory (T_{H2}) T_H subsets characterized by secretion of IFN γ and IL-12 or IL-4 and TGF- β , respectively (45, 50).

CONCLUSION

The multifunctional, context-dependent activities of TGF- β described in this article are by no measure unique to its actions in the immune system, but rather, they exemplify the basic tenet that has defined the function of this molecule, as stated succinctly by MB Sporn: "The function of TGF- β ... is not to have an intrinsic action, but to serve as a mechanism for coupling a cell to its environment, so that the cell has the plasticity to respond appropriately to changes in its environment or changes in its own state" (132). Thus, the ability of TGF- β to enhance the induction of an immune response is often accompanied by the increased expression of TGF- β itself, which then often serves to dampen the response or inhibit the activated cell populations.

It is significant that each member of the various hematopoietic lineages can be included in the long list of cells responsive to TGF- β . Though we chose to focus on the differentiation and function of just a few highly specialized leukocytes, the expression and function of TGF- β in NK cells, neutrophils and other myeloid lineages, and various hematopoietic progenitors must also be recognized. In each instance, TGF- β clearly provides regulatory signals that

are shaped by ongoing cellular interactions, by the cytokine context, and by the relative state of differentiation of the responsive cell.

As we continue to advance our understanding of the important and essential functions of this cytokine, it is critical that we begin to consider practical and clinically useful approaches to manipulate both the expression of and the response to this cytokine in those disorders where a role for TGF- β has been implicated.

Visit the *Annual Reviews* home page at
<http://www.AnnualReviews.org>.

Literature Cited

1. Paul WE, Seder RA. 1994. Lymphocyte responses and cytokines. *Cell* 76:241–51
2. Ruscetti FW, Palladino MA. 1991. Transforming growth factor-beta and the immune system. *Prog. Growth Factor Res.* 3:159–75
3. Wahl SM. 1994. Transforming growth factor beta: the good, the bad, and the ugly. *J. Exp. Med.* 180:1587–90
4. McCartney-Francis NL, Wahl SM. 1994. Transforming growth factor beta: a matter of life and death. *J. Leukocyte Biol.* 55:401–9
5. Letterio JL, Roberts AB. 1997. TGF- β : a critical modulator of immune cell function. *Clin. Immunol. Immunopathol.* 84(3):244–50
6. Roberts AB, Sporn MB. 1990. The transforming growth factors- β . In *Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors*, ed. MB Sporn, AB Roberts, pp. 419–72. New York: Springer-Verlag
7. Attisano L, Wrana JL. 1996. Signal transduction by members of the transforming growth factor-beta superfamily. *Cytokine Growth Factor Rev.* 7:327–39
8. Sporn MB, Roberts AB. 1992. Autocrine secretion—10 years later. *Ann. Intern. Med.* 117:408–14
9. Letterio JJ, Bottinger E. 1997. Studies in TGF- β knockout and dominant-negative type II receptor transgenic mice. *Min. Electrolyte Metab.* In press
10. Xie J, Gallagher G. 1992. Transforming growth factor-beta is not the major soluble immunosuppressor in the microenvironments of human breast tumours. *Anticancer Res.* 12:2117–21
11. Schiott A, Sjögren HO, Lindvall M. 1996. Monocyte-dependent costimulatory effect of TGF- β 1 on rat T-cell activation. *Scand. J. Immunol.* 44:252–60
12. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. 1986. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. *J. Exp. Med.* 163:1037–50
13. Ahuja SS, Paliogianni F, Yamada H, Balow JE, Boumpas DT. 1993. Effect of transforming growth factor-beta on early and late activation events in human T cells. *J. Immunol.* 150:3109–18
14. Espevik T, Waage A, Faxvaag A, Shalaby MR. 1990. Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of interleukin-1 beta and transforming growth factor-beta. *Cell Immunol.* 126:47–56
15. Fargeas C, Wu CY, Nakajima T, Cox D, Nutman T, Delespesse G. 1992. Differential effect of transforming growth factor beta on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes. *Eur. J. Immunol.* 22:2173–76
16. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA Jr. 1987. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. *J. Exp. Med.* 166:571–76
17. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC. 1991. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8⁺ T lymphocytes. Inhibition by transforming growth factor-beta. *J. Immunol.* 146:3289–97
18. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA. 1988. Transforming growth factor-beta inhibits the in vitro

- generation of lymphokine-activated killer cells and cytotoxic T cells. *Cancer Immunol. Immunother.* 26:95–100
19. Cerwenka A, Bevec D, Majdic O, Knapp W, Holter W. 1994. TGF- β 1 is a potent inducer of human effector T cells. *J. Immunol.* 153:4367–77
 20. Cerwenka A, Kovar H, Majdic O, Holter W. 1996. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF- β 1. *J. Immunol.* 156:459–64
 21. Rich S, Van Nood N, Lee HM. 1996. Role of alpha 5 beta 1 integrin in TGF- β 1-costimulated CD8⁺ T cell growth and apoptosis. *J. Immunol.* 157:2916–23
 22. Zhang X, Giangreco L, Broome HE, Dargan CM, Swain SL. 1995. Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. *J. Exp. Med.* 182:699–709
 23. Petrie HT, Pearse M, Scollay R, Shortman K. 1990. Development of immature thymocytes: initiation of CD3, CD4, and CD8 acquisition parallels down-regulation of the interleukin 2 receptor alpha chain. *Eur. J. Immunol.* 20:2813–15
 24. Nikolic-Zugic J. 1991. Phenotypic and functional stages in the intrathymic development of alpha beta T cells. *Immunol. Today* 12:65–70
 25. Suda T, Zlotnik A. 1991. IL-7 maintains the T cell precursor potential of CD3⁻CD4⁻CD8⁻ thymocytes. *J. Immunol.* 146:3068–73
 26. Suda T, Zlotnik A. 1992. In vitro induction of CD8 expression on thymic pre-T cells. II. Characterization of CD3⁻CD4⁻CD8⁺ cells generated in vitro by culturing CD25⁺CD3⁻CD4⁻CD8⁻ thymocytes with T cell growth factor-beta and tumor necrosis factor-alpha. *J. Immunol.* 149:71–76
 27. Inge TH, McCoy KM, Susskind BM, Barrett SK, Zhao G, Bear HD. 1992. Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes. *J. Immunol.* 148:3847–56
 28. Mossalayi MD, Mentz F, Ouaz F, Dalloul AH, Blanc C, Debre P, Russetti FW. 1995. Early human thymocyte proliferation is regulated by an externally controlled autocrine transforming growth factor-beta 1 mechanism. *Blood* 85:3594–3601
 29. Plum J, De Smedt M, Leclercq G, Vandekerckhove B. 1995. Influence of TGF- β on murine thymocyte development in fetal thymus organ culture. *J. Immunol.* 154:5789–98
 30. Takahama Y, Letterio JJ, Suzuki H, Farr AG, Singer A. 1994. Early progression of thymocytes along the CD4/CD8 developmental pathway is regulated by a subset of thymic epithelial cells expressing transforming growth factor beta. *J. Exp. Med.* 179:1495–1506
 31. Tang J, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Ryan DH. 1997. TGF- β down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. *J. Immunol.* 159:117–25
 32. Chantry D, Turner M, Feldmann M. 1989. Interleukin 7 (murine pre-B cell growth factor/lymphopoietin 1) stimulates thymocyte growth: regulation by transforming growth factor beta. *Eur. J. Immunol.* 19:783–86
 33. Seder RA, Paul WE. 1994. Acquisition of lymphokine-producing phenotype by CD4⁺ T cells. *Annu. Rev. Immunol.* 12:635–73
 34. Coffman RL, von der Weid T. 1997. Multiple pathways for the initiation of T helper 2 (Th2) responses. *J. Exp. Med.* 185:373–75
 35. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA. 1997. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4⁺ T cells. *J. Exp. Med.* 185:461–69
 36. Szabo SJ, Dighe AS, Gubler U, Murphy KM. 1997. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. *J. Exp. Med.* 185:817–24
 37. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia F. 1997. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. *J. Exp. Med.* 185:825–31
 38. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. *Science* 265:1237–40
 39. Fukaura H, Kent SC, Pietrusiewicz MJ, Khoury SJ, Weiner HL, Hafler DA. 1996. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. *J. Clin. Invest.* 98:70–77
 40. Bridoux F, Badou A, Saoudi A, Bernard I, Druet E, Pasquier R, Druet P, Pelletier L. 1997. Transforming growth factor beta (TGF-beta)-dependent inhibition

- of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines. *J. Exp. Med.* 185:1769-75
41. Swain SL, Huston G, Tonkonogy S, Weinberg A. 1991. Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. *J. Immunol.* 147:2991-3000
 42. Sad S, Mosmann TR. 1994. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. *J. Immunol.* 153:3514-22
 43. Pawelec G, Rehbein A, Schlotz E, Friccius H, Pohla H. 1996. Cytokine modulation of TH1/TH2 phenotype differentiation in directly alloresponsive CD4⁺ human T cells. *Transplantation* 62:1095-1101
 44. Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, Twardzik DR, Reed SG. 1992. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. *Science* 257:545-48
 45. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M. 1997. Reciprocal IFN-gamma and TGF- β responses regulate the occurrence of mucosal inflammation. *Immunol. Today* 18:61-64
 46. Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rude E, Germann T. 1994. T helper type 1 development of naive CD4⁺ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. *Eur. J. Immunol.* 24:793-98
 47. Pardoux C, Asselin-Paturel C, Chehimi J, Gay F, Mami-Chouaib F, Chouaib S. 1997. Functional interaction between TGF- β and IL-12 in human primary allogeneic cytotoxicity and proliferative response. *J. Immunol.* 158:136-43
 48. Marth T, Strober W, Seder RA, Kelsall BL. 1997. Regulation of transforming growth factor-beta production by interleukin-12. *Eur. J. Immunol.* 27:1213-20
 49. Marth T, Strober W, Kelsall BL. 1996. High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF- β secretion and T cell apoptosis. *J. Immunol.* 157:2348-57
 50. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. 1996. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4⁺ T cells. *J. Exp. Med.* 183:2669-74
 51. Steinman RM. 1991. The dendritic cell system and its role in immunogenicity. *Annu. Rev. Immunol.* 9:271-96
 52. Strobl H, Riedl E, Scheinecker C, Bello-Fernandez C, Pickl WF, Rappersberger K, Majdic O, Knapp W. 1996. TGF- β 1 promotes in vitro development of dendritic cells from CD34⁺ hemopoietic progenitors. *J. Immunol.* 157:1499-507
 53. Riedl E, Strobl H, Majdic O, Knapp W. 1997. TGF- β 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. *J. Immunol.* 158:1591-97
 54. Borkowski TA, Letterio JJ, Farr AG, Udey MC. 1996. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. *J. Exp. Med.* 184:2417-22
 55. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. *Nature* 359:693-99
 56. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. *Proc. Natl. Acad. Sci. USA* 90:770-74
 57. Borkowski TA, Letterio JJ, Mackall CL, Saitoh A, Wang X-J, Roop DR, Gress RE, Udey MC. 1997. A role for TGF- β 1 in Langerhans cell biology: further characterization of the epidermal Langerhans cell defect in TGF- β 1 null mice. *J. Clin. Invest.* 100(3):575-81
 58. Imai Y, Yamakawa M. 1996. Morphology, function and pathology of follicular dendritic cells. *Pathol. Int.* 46:807-33
 59. Holder MJ, Knox K, Gordon J. 1992. Factors modifying survival pathways of germinal center B cells. Glucocorticoids and transforming growth factor-beta, but not cyclosporin A or anti-CD19, block surface immunoglobulin-mediated rescue from apoptosis. *Eur. J. Immunol.* 22:2725-28
 60. Gordon J, Katira A, Holder M, MacDonald I, Pound J. 1994. Central role of CD40 and its ligand in B lymphocyte responses

- to T-dependent antigens. *Cell Mol. Biol.* 40(Suppl. 1):1-13
61. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. 1986. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. *J. Immunol.* 137:3855-60
 62. Snapper CM, Waegell W, Beernink H, Dasch JR. 1993. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. *J. Immunol.* 151:4625-36
 63. Warner GL, Ludlow JW, Nelson DA, Gaur A, Scott DW. 1992. Anti-immunoglobulin treatment of murine B-cell lymphomas induces active transforming growth factor beta but pRB hypophosphorylation is transforming growth factor beta independent. *Cell Growth Differ.* 3:175-81
 64. Matthes T, Werner-Favre C, Tang H, Zhang X, Kindler V, Zubler RH. 1993. Cytokine mRNA expression during an in vitro response of human B lymphocytes: kinetics of B cell tumor necrosis factor alpha, interleukin (IL)6, IL-10, and transforming growth factor beta 1 mRNAs. *J. Exp. Med.* 178:521-28
 65. Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. 1995. TGF- β 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. *J. Immunol.* 154:1634-43
 66. Lotz M, Ranheim E, Kipps TJ. 1994. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. *J. Exp. Med.* 179:999-1004
 67. Newcom SR, Tagra KK, Kadin ME. 1992. Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta. *Am. J. Pathol.* 140:709-18
 68. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. 1994. Loss of receptors for transforming growth factor beta in human T-cell malignancies. *Proc. Natl. Acad. Sci. USA* 91:6002-6
 69. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME. 1997. Loss of functional cell surface transforming growth factor beta (TGF- β) type 1 receptor correlates with insensitivity to TGF- β in chronic lymphocytic leukemia. *Proc. Natl. Acad. Sci. USA* 94:5877-81
 70. Berg DJ, Lynch RG. 1991. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes. *J. Immunol.* 146:2865-72
 71. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li XF, Shimizu J, Fujiwara H, Hamaoka T. 1991. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. *J. Immunol.* 146:1077-82
 72. Stavnezer J. 1996. Transforming growth factor beta. In *Cytokine Regulation of Humoral Immunity: Basic and Clinical Aspects*, ed. CM Snapper, pp. 289-324. New York: Wiley
 73. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N. 1995. SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF- β knockout mice. *J. Immunol.* 155:3205-12
 74. Bogdan C, Nathan C. 1993. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. *Ann. NY Acad. Sci.* 685:713-39
 75. Wahl SM. 1992. Transforming growth factor beta (TGF- β) in inflammation: a cause and a cure. *J. Clin. Immunol.* 12:61-74
 76. Border WA, Noble NA. 1994. Transforming growth factor beta in tissue fibrosis. *N. Engl. J. Med.* 331:1286-92
 77. Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB. 1987. Expression and secretion of type beta transforming growth factor by activated human macrophages. *Proc. Natl. Acad. Sci. USA* 84:6020-24
 78. Grotendorst GR, Smale G, Pencev D. 1989. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. *J. Cell Physiol.* 140:396-402
 79. Flaumenhaft R, Kojima S, Abe M, Rifkin DB. 1993. Activation of latent transforming growth factor beta. *Adv. Pharmacol.* 24:51-76
 80. Barcellos-Hoff MH. 1996. Latency and activation in the control of TGF- β . *J. Mammary Gland Biol. Neoplasia* 1:351-61
 81. Nunes I, Shapiro RL, Rifkin DB. 1995. Characterization of latent TGF- β activation by murine peritoneal macrophages. *J. Immunol.* 155:1450-59
 82. Khalil N, Corne S, Whitman C, Yacyszyn

- H. 1996. Plasmin regulates the activation of cell-associated latent TGF- β 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. *Am. J. Respir. Cell Mol. Biol.* 15:252-59
83. Yesner LM, Huh HY, Pearce SF, Silverstein RL. 1996. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. *Arterioscler. Thromb. Vasc. Biol.* 16:1019-25
 84. Khalil N, Yahaulaeshet T, Murphy-Ullrich JE, Silverstein R, Green-Johnson J, Mai S, Greenberg AH. 1997. Activation of alveolar macrophage derived L-TGF- β 1 by plasmin requires interaction with TSP-1 and the TSP-1 cell surface receptor CD36. *J. Cell Biol.* Submitted
 85. Falcone DJ, McCaffrey TA, Mathew J, McAdam K, Borth W. 1995. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor. *J. Cell Physiol.* 164:334-43
 86. Celada A, Maki RA. 1992. Transforming growth factor-beta enhances the M-CSF and GM-CSF-stimulated proliferation of macrophages. *J. Immunol.* 148:1102-5
 87. Fan K, Ruan Q, Sensenbrenner L, Chen B. 1992. Transforming growth factor-beta 1 bifunctionally regulates murine macrophage proliferation. *Blood* 79:1679-85
 88. Sato Y, Kobori S, Sakai M, Yano T, Higashi T, Matsumura T, Morikawa W, Terano T, Miyazaki A, Horiuchi S, Shichiri M. 1996. Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-beta activation. *Atherosclerosis* 125:15-26
 89. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. 1987. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. *Proc. Natl. Acad. Sci. USA* 84:5788-92
 90. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. 1988. Transforming growth factor-beta (TGF β) is chemotactic for human monocytes and induces their expression of angiogenic activity. *Biochem. Biophys. Res. Commun.* 157:793-800
 91. McCartney-Francis N, Mizel D, Wong H, Wahl L, Wahl S. 1990. TGF- β regulates production of growth factors and TGF- β by human peripheral blood monocytes. *Growth Factors* 4:27-35
 92. Bauvois B, Rouillard D, Sanceau J, Wietzerbin J. 1992. IFN-gamma and transforming growth factor-beta 1 differently regulate fibronectin and laminin receptors of human differentiating monocytic cells. *J. Immunol.* 148:3912-19
 93. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. 1993. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. *Proc. Natl. Acad. Sci. USA* 90:4577-81
 94. Bauvois B, Van Weyenbergh J, Rouillard D, Wietzerbin J. 1996. TGF- β 1-stimulated adhesion of human mononuclear phagocytes to fibronectin and laminin is abolished by IFN-gamma: dependence on alpha 5 beta 1 and beta 2 integrins. *Exp. Cell Res.* 222:209-17
 95. Welch GR, Wong HL, Wahl SM. 1990. Selective induction of Fc gamma RIII on human monocytes by transforming growth factor-beta. *J. Immunol.* 144:3444-48
 96. Rose DM, Fadok VA, Riches DW, Clay KL, Henson PM. 1995. Auto-crine/paracrine involvement of platelet-activating factor and transforming growth factor-beta in the induction of phosphatidylserine recognition by murine macrophages. *J. Immunol.* 155:5819-25
 97. Turner M, Chantry D, Katsikis P, Berger A, Brennan FM, Feldmann M. 1991. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. *Eur. J. Immunol.* 21:1635-39
 98. MacDermott RP. 1996. Alterations of the mucosal immune system in inflammatory bowel disease. *J. Gastroenterol.* 31:907-16
 99. Vodovotz Y, Bogdan C. 1994. Control of nitric oxide synthase expression by transforming growth factor-beta: implications for homeostasis. *Prog. Growth Factor. Res.* 5:341-51
 100. Chao CC, Molitor TW, Gekker G, Murtaugh MP, Peterson PK. 1991. Cocaine-mediated suppression of superoxide production by human peripheral blood mononuclear cells. *J. Pharmacol. Exp. Ther.* 256:255-58
 101. Tsunawaki S, Sporn M, Nathan C. 1989. Comparison of transforming growth factor-beta and a macrophage-deactivating polypeptide from tumor cells. Differences in antigenicity and mechanism of action. *J. Immunol.* 142:3462-68
 102. Gazzinelli RT, Oswald IP, Hiemy S, James SL, Sher A. 1992. The microbicidal activity of interferon-gamma-treated macrophages against *Trypanosoma cruzi* involves an L-arginine-dependent, nitric oxide-mediated mechanism inhibi-

- table by interleukin-10 and transforming growth factor-beta. *Eur. J. Immunol.* 22: 2501-6
103. Barral-Netto M, Barral A. 1994. Transforming growth factor-beta in tegumentary leishmaniasis. *Braz. J. Med. Biol. Res.* 27:1-9
 104. Ming M, Ewen ME, Pereira ME. 1995. Trypanosome invasion of mammalian cells requires activation of the TGF- β signaling pathway. *Cell* 82:287-96
 105. Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG. 1993. Transforming growth factor beta as a virulence mechanism for *Leishmania braziliensis*. *Proc. Natl. Acad. Sci. USA* 90:3442-46
 106. Silva JS, Twardzik DR, Reed SG. 1991. Regulation of *Trypanosoma cruzi* infections in vitro and in vivo by transforming growth factor beta (TGF- β). *J. Exp. Med.* 174:539-45
 107. Czarniecki CW, Chiu HH, Wong GH, McCabe SM, Palladino MA. 1988. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. *J. Immunol.* 140:4217-23
 108. Gollnick SO, Cheng HL, Grande CC, Thompson D, Tomasi TB. 1995. Effects of transforming growth factor-beta on bone marrow macrophage Ia expression induced by cytokines. *J. Interferon Cytokine Res.* 15:485-91
 109. Barral A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, Bittencourt AL, Reed S, Carvalho EM, Barral-Netto M. 1995. Transforming growth factor-beta in human cutaneous leishmaniasis. *Am. J. Pathol.* 147:947-54
 110. Champisi J, Young LS, Bermudez LE. 1995. Production of TNF-alpha, IL-6 and TGF- β , and expression of receptors for TNF-alpha and IL-6, during murine *Mycobacterium avium* infection. *Immunology* 84:549-54
 111. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. 1991. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. *Proc. Natl. Acad. Sci. USA* 88:2918-21
 112. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. 1992. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. *Proc. Natl. Acad. Sci. USA* 89:7375-79
 113. Racke MK, Cannella B, Albert P, Sporn M, Raine CS, McFarlin DE. 1992. Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. *Int. Immunol.* 4:615-20
 114. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. 1992. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. *Proc. Natl. Acad. Sci. USA* 89:421-25
 115. Chen Y, Inobe J, Weiner HL. 1995. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4⁺ and CD8⁺ cells mediate active suppression. *J. Immunol.* 155:910-16
 116. Letterio JJ, Kulkarni AB. 1997. The transforming growth factor- β 1 knockout mouse. In *Cytokine Knockout Mice*, ed. S Durum, K Muegge. Totow, NJ: Humana. In press
 117. Steinberg AD. 1994. MRL-lpr/lpr disease: theories meet Fas. *Semin. Immunol.* 6:55-69
 118. Lowrance JH, O'Sullivan FX, Caver TE, Waegell W, Gresham HD. 1994. Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. *J. Exp. Med.* 180:1693-1703
 119. Rowley DA, Becken ET, Stach RM. 1995. Autoantibodies produced spontaneously by young lpr mice carry transforming growth factor beta and suppress cytotoxic T lymphocyte responses. *J. Exp. Med.* 181:1875-80
 120. Caver TE, O'Sullivan FX, Gold LI, Gresham HD. 1996. Intracellular demonstration of active TGF- β 1 in B cells and plasma cells of autoimmune mice. IgG-bound TGF- β 1 suppresses neutrophil function and host defense against *Staphylococcus aureus* infection. *J. Clin. Invest.* 98:2496-506
 121. Stach RM, Rowley DA. 1993. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens. *J. Exp. Med.* 178:841-52
 122. Gresham HD, Ray CJ, O'Sullivan FX. 1991. Defective neutrophil function in the autoimmune mouse strain MRL/lpr. Potential role of transforming growth factor-beta. *J. Immunol.* 146:3911-21
 123. Bouchard C, Galinha A, Tartour E, Fridman WH, Sautes C. 1995. A transforming growth factor beta-like immunosuppressive factor in immunoglobulin G-binding

- factor. *J. Exp. Med.* 182:1717–26
124. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang ZQ, Sanders PW. 1995. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. *Am. J. Pathol.* 147:375–85
 125. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. 1995. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin I. *J. Biol. Chem.* 270:7304–10
 126. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB. 1994. Maternal rescue of transforming growth factor-beta 1 null mice. *Science* 264:1936–38
 127. Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB. 1993. Transforming growth factor beta 1 (TGF- β 1) controls expression of major histocompatibility genes in the post-natal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF- β 1 null mouse phenotype. *Proc. Natl. Acad. Sci. USA* 90:9944–48
 128. Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S. 1994. Immune dysregulation in TGF- β 1-deficient mice. *J. Immunol.* 153:1936–46
 129. Hines KL, Kulkarni AB, McCarthy JB, Tian H, Ward JM, Christ M, McCartney-Francis NL, Furcht LT, Karlsson S, Wahl SM. 1994. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. *Proc. Natl. Acad. Sci. USA* 91:5187–91
 130. Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, Nakabayashi T, Mackall CL, Gress RE, Roberts AB. 1996. Autoimmunity associated with TGF- β 1-deficiency in mice is dependent on MHC class II antigen expression. *J. Clin. Invest.* 98:2109–19
 131. Reimold AM, Kara CJ, Rooney JW, Glimcher LH. 1993. Transforming growth factor beta 1 repression of the HLA-DR alpha gene is mediated by conserved proximal promoter elements. *J. Immunol.* 151:4173–82
 132. Sporn MB, Roberts AB. 1990. TGF- β : problems and prospects. *Cell Regul.* 1:875–82